Nutriband Reports 51% Revenue Growth, Advances AVERSA Fentanyl Program with Strong Cash Position

Nutriband Inc. (NASDAQ: NTRB) reported financial results for the six months ended July 31, 2025, showing revenue of $1.29 million, representing a 50.87% year-over-year increase. The company maintains a strong cash position of $6.9 million, which it states will support the advancement of its lead product candidate, AVERSA Fentanyl. The company has scheduled a Type C FDA meeting for September 18 to discuss the development pathway for this innovative product.

The significance of AVERSA Fentanyl lies in its potential to become the first and only abuse-deterrent transdermal fentanyl product globally. What makes this development particularly noteworthy is that the New Drug Application (NDA) will rely solely on data from a single Phase 1 Human Abuse Potential study, with no Phase 2 or Phase 3 trials required. This streamlined regulatory pathway could accelerate the product's time to market while addressing the critical need for abuse-deterrent opioid formulations.

Market projections indicate substantial commercial potential for AVERSA Fentanyl, with peak annual sales estimated between $80 million and $200 million. The company's second program, AVERSA Buprenorphine, is projected to reach peak annual sales of up to $130 million. Revenue growth has been supported by the company's Pocono Pharma contract manufacturing subsidiary, which contributed to record first-half performance. Additional information about the company's developments is available at https://ibn.fm/NTRB.

The advancement of AVERSA technology represents an important development in addressing the opioid crisis by preventing abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The technology can be incorporated into any transdermal patch, offering broad application potential beyond fentanyl products. The company's financial stability and strategic focus on abuse-deterrent technologies position it to make significant contributions to pharmaceutical safety and public health initiatives.